Traverse Biosciences

NIH sees a need for speed in Traverse Biosciences

By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel drug candidates for the treatment of inflammatory diseases affecting animals and humans, has landed one of 80 annual slots in the CAP, a nine-month program hosted by the NIH and the Larta Institute, a California-based networking group promoting international innovation. The NIH CAP – which…


Heads scratched as Chem-Master gets the boot

By GREGORY ZELLER // A biotech manufacturer with a 23-year history of servicing Stony Brook University researchers and startups is being evicted from the university’s Chemistry Building – and nobody seems entirely sure why. Chem-Master International, a producer of unique chemical compounds for research and commercial development, has operated inside the Chemistry Building since it launched in 1994, thanks to a “revocable permit” – special SUNY dispensation allowing nontraditional programs and outside entities to occupy…


New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…


Still cutting its teeth, Traverse set for stellar 2017

By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may ultimately pale compared to what’s shaping up as a potentially enormous 2017 for the Stony Brook biotech and its flagship pharmaceutical. Fueled primarily by a $1.32 million Phase II Small Business Technology Transfer award granted by the National Institutes of Health in August to the…


Traverse sinks teeth into human periodontal study

By GREGORY ZELLER // It seems everyone wants a piece of TRB-N0224. Already being tested as a potential treatment for lung injuries and for periodontal disease in dogs and cats, the flagship formula patented by Stony Brook-based Traverse Biosciences will now be pitted against inflammatory diseases threating bone and tissue around human teeth. The National Institutes of Health has awarded Traverse Biosciences, in partnership with Stony Brook University’s School of Dental Medicine, a $1.32 million…


Traverse, SUNY, DoD set big test for TRB-N0224

Stony Brook-based biotech Traverse Biosciences will share a Department of Defense award with SUNY Upstate Medical University to fund a critical field test of Traverse’s leading drug candidate. The effectiveness of TRB-N0224 as a treatment for lung injuries – including acute respiratory distress syndrome, a common condition in critically ill patients with a mortality rate as high as 50 percent – will be put to the test via a DoD Peer Reviewed Medical Research Program…


Traverse Biosciences lands key seed investment

By GREGORY ZELLER // A critical seed investment will help Traverse Biosciences commercialize pharmaceutical candidates licensed from the SUNY Research Foundation. The circa-2013 Stony Brook-based biotech has secured $500,000 in convertible debt financing in a round led by Excell Partners, a Rochester-based venture capital fund partial to early-stage, high-tech startups. The SUNY Research Foundation added an undisclosed investment to Excell Partner’s $100,000 stake, while a collection of 10 accredited angel investors – “almost exclusively from…


Traverse awarded much-awaited patent

A Stony Brook-based bioscience startup has landed a long-awaited U.S. patent, marking a major step toward commercializing several novel drug candidates. The U.S. Patent and Trademark Office has granted Patent No. 9,187,406 to Traverse Biosciences, a 2013 startup residing in the Long Island High Technology Incubator on the Stony Brook University campus. Titled “Curcumin Analogues as Zinc Chelators and Their Uses,” the patent involves compounds developed by SBU faculty members Lorne Golub and Francis Jonson…


Traverse CEO Joseph Scaduto

Traverse Biosciences inks R&D, licensing deal

BY GREGORY ZELLER // Stony Brook-based startup Traverse Biosciences has inked an exclusive R&D agreement that could lead to an $8 million sublicensing option. Traverse, a resident of the Long Island High Technology Incubator at Stony Brook University, announced today that it has executed a $250,000 cooperative research and development agreement with Kansas-based Aratana Therapeutics to advance Traverse’s leading drug candidate, TRB-N0224, a potential treatment for periodontal disease in dogs and cats. Traverse Biosciences has…


Traverse CEO Joseph Scaduto

Traverse readies the move to market

BY GREGORY ZELLER // Armed with a just-executed licensing agreement for a suite of anti-inflammatory drug therapies, two-year-old Traverse Biosciences is stepping up efforts to land the investors and strategic partners necessary for rapid product development. The licensing agreement with the SUNY Research Foundation gives Traverse rights to compounds developed by Stony Brook University faculty members Lorne Golub and Francis Johnson and known as — science alert — polyenolic zinc-binding agents. Their leading drug candidate,…